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Introduction
Rheumatoid arthritis (RA) is traditionally con-
sidered as the prototype of destructive arthritis. 
Chronic inflammation of the synovial membrane 
in RA indeed results in bone and cartilage resorp-
tion through the production of molecules that 
support the differentiation and activation of oste-
oclasts as well as enzymes which degrade articu-
lar cartilage and bone [Schett, 2007; Walsh and 
Gravallese, 2010]. The central importance of joint 
remodeling processes in RA pathology is high-
lighted by the fact that the assessment of struc-
tural damage using imaging techniques is a major 
diagnostic, monitoring, and outcome parameter 
in both clinical trials and routine clinical practice 
[Lillegraven et al. 2012]. Joint destruction often 
begins very early and progresses rapidly within 
the first years from symptoms onset [Lindqvist 
et al. 2003; Machold et al. 2007]. The severity of 
bone and cartilage damage does have functional 
implications at least in the later stages of the 
disease, as suggested by multiple studies demon-
strating the association between increasing joint 
destruction over time and progressive decline in 
physical function [Drossaers-Bakker et al. 1999; 
Scott et al. 2000; Welsing et al. 2001]. Preventing 
joint damage is therefore a key measure of current 
and novel therapies and treatment strategies in RA.
Despite common clinical and pathophysiological 
features, RA appears to consist of a variety of dif-
ferent phenotypes in terms of clinical expression 
and long-term course, including the extent and 
rate of progression of joint damage. Studies on 
very early arthritis (≤3 months from symptom 
onset) have shown that up to 20% of RA patients 
already present with erosions at baseline despite 
early referral [Nell et al. 2004; Machold et al. 
2007], and substantial structural damage further 
develops even during disease-modifying antirheu-
matic drug (DMARD) therapy [Machold et al. 
2007; Rezaei et al. 2012]. Such a proportion may 
be even higher in selected cohorts of patients with 
aggressive RA eligible for randomized clinical 
trials, such as in the BeSt study, where erosive dis-
ease is observed in up to 70% of the cases [Visser 
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et al. 2010]. On the other hand, rheumatologists 
in daily clinical practice well appreciate that a 
considerable number of patients does not experi-
ence any erosion even after long-term disease. 
Following the greater availability of treatment 
targets and options, the prospect of distinguishing 
which patient with early RA is to run a severe 
disease course and which is not is, at present, one 
of the main challenges in the management of RA. 
Early predictors of disease outcome would indeed 
ideally channel aggressive treatments to patients 
most at risk, thus optimizing efficacy, adverse 
events and socioeconomic costs.
A number of demographic, immunologic and 
genetic factors have been variably associated 
with more severe outcomes in RA at the popula-
tion level, including age, gender, autoantibody 
status and human leukocyte antigen (HLA) gen-
otyping [Markatseli et al. 2010]. In particular, 
positivity for anticitrullinated protein antibod-
ies (ACPAs) is currently recognized as one of 
the strongest independent predictors of erosive 
disease [Meyer et al. 2003; Forslind et al. 2004; 
van der Helm-van Mil et al. 2005; Syversen et al. 
2008]. In the study by Syversen and colleagues 
[Syversen et al. 2008], a positive ACPA test pre-
dicted radiographic progression after 10 years of 
follow up with an odds ratio (OR) of 4 in a mul-
tiple regression model also including female 
gender, high erythrocyte sedimentation rate 
(ESR) and IgM rheumatoid factor (RF) positiv-
ity. Combined together, the probability of radio-
graphic progression was 92.5% in females with a 
positive ACPA and IgM RF test and a high ESR 
[Syversen et al. 2008]. Despite excellent sensi-
tivity, however, specificity may be unsatisfactory. 
A recent study by Liao and colleagues [Liao et al. 
2011] failed to demonstrate a significant value 
of the ACPA test in predicting erosion-free status 
after 2 years of follow up. Many efforts are thus 
being made in the search for additional markers 
able to identify different radiographic outcomes 
since the earliest stages of the disease. As joint 
destruction in RA is the result of the cumulative 
burden of inflammation, predictive factors of 
radiographic progression may be searched within 
variables associated with the severity of inflam-
mation and its persistence over time. Here we 
focus on new and renewed data which make the 
assessment of synovitis through clinical, imag-
ing, histopathologic and serologic examinations, 
a valuable tool to look into disease heterogeneity 
in RA.
Clinical assessment
Clinical evaluation of involved joints through 
formal joint counts remains the cornerstone of 
the quantitative assessment of inflammation in 
RA. Physical examination per se is thus expected 
to provide important information on different 
radiological outcomes of the disease. Accordingly, 
cumulative swollen joint counts (SJCs) have 
repeatedly been shown to be associated with joint 
damage progression over time at both the patient 
and the individual joint level [Van Leeuwen et al. 
1994; Smolen et al. 2006; Boers et al. 2001; 
Klarenbeek et al. 2010]. A proof of concept of the 
tight relationship between clinically active joints 
and structural changes is provided by the demon-
stration that repair (the opposite of progression), 
although it remains an extremely rare feature in 
RA [van der Linden et al. 2010], may only occur 
in association with improvement or cessation of 
clinical swelling [Lukas et al. 2010]. The crucial 
importance of joint assessment to predict radio-
graphic outcomes in patients with RA is further 
highlighted by recent evidences showing that joint 
damage progression in remission is driven by 
residual swollen joints [Aletaha and Smolen, 
2011], which appear to be more predictive com-
pared with other variables of inflammation such 
as acute phase reactants [Aletaha et al. 2011]. The 
association between clinical inflammation and 
joint destruction has strong foundation in patients 
treated synthetic DMARDs. It is, however, 
worthwhile to underline that the relationship is 
not as clearly defined in patients treated with 
biologic agents, in which an apparent dissociation 
between clinical and radiographic outcomes can 
be observed. Patients with clinical disease activity 
treated with anti-TNF (tumor necrosis factor) 
agents may indeed have no evidence of erosive 
progression [Smolen et al. 2005]. Accordingly, 
SJCs averaged over time appear associated with 
radiographic outcomes during methotrexate mon-
otherapy but not during combination therapy with 
infliximab [Smolen et al. 2006]. The fact that 
treatment choice per se is a major determinant of 
radiographic progression is further highlighted by 
recent evidence demonstrating that other predic-
tors (autoantibody status, acute phase reactants, 
baseline erosion scores), alone or in combination, 
perform differently in patients receiving different 
treatment strategies [Visser et al. 2010].
If structural outcomes can collectively be deter-
mined by persistent joint swelling, a clinically 
relevant issue is whether the severity of joint 
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involvement at baseline may be equally predictive 
of the rate of radiographic progression over time. 
This would imply that patients with high levels of 
disease activity at presentation will continue to do 
badly. The relationship between the amount of 
initial joint inflammation and the persistence of 
inflammation itself, however, is not so obvious 
[Drouin and Haraoui, 2010]. Accordingly, there 
are conflicting results from the literature concern-
ing the predictive value of a single assessment of 
SJCs at baseline for radiographic damage. In the 
long-term study by Kaarela [Kaarela, 1985], the 
number of swollen joints was an independent pre-
dictive factor of radiological progression. This 
association was either weaker [Smolen et al. 2006] 
or not confirmed in more recent studies [Combe 
et al. 2001; Machold et al. 2007; Courvoisier et al. 
2008]. Such a discrepancy is also reflected by the 
variable inclusion of SJC in the recently developed 
matrix risk models for the prediction of rapid 
radiographic progression in RA [Vastesaeger et al. 
2009; Visser et al. 2010]. In contrast, re-assessment 
of joint involvement soon after initiation of 
therapy seems more informative on radiographic 
outcomes [Smolen et al. 2006], in line with the 
notion that the strongest determinant of persis-
tent disease activity is the level of disease activity 
itself after the first few months of treatment 
[Aletaha et al. 2007].
Imaging assessment
Modern ultrasonography (US) enables clinicians 
to sensitively assess soft-tissue structures, and 
the use of power Doppler (PD) further extends 
the analysis to synovial vascularity. Being more 
sensitive than clinical examination in detecting 
synovial inflammation [Naredo et al. 2005] and 
in discriminating between ‘active’ and ‘inactive’ 
joints, US-PD was expected to provide additional 
value compared with manual joint counts in pre-
dicting the evolution of RA. Using radiographic 
progression as a final measure of disease out-
come, results have been however conflicting. If 
on the one hand time-integrated values of US-PD 
correlate well with the amount of joint damage 
progression [Naredo et al. 2007], a single time 
assessment at baseline has not been consistently 
associated with radiographic outcomes [Taylor 
et al. 2004; Naredo et al. 2007; Reynolds et al. 
2009; Fukae et al. 2010]. Thus, similarly to SJCs, 
measuring cumulative synovial inflammation over 
time is more informative compared with single 
time point measurements, and highest levels of 
synovitis at baseline do not appear to predict per 
se worst disease evolution, irrespective of how 
‘sensitive’ synovial inflammation is measured. 
Also, it is important to emphasize that the very 
high sensitivity of advanced PD equipments may 
to some extent compromise specificity. PD activ-
ity is indeed observed in the hand and finger 
joints of a number of healthy individuals [Terslev 
et al. 2008]. Similarly, US-PD measurements 
may be affected by physiological or pharmaceuti-
cal stimuli also in RA patients [Ellegaard et al. 
2009; Zayat et al. 2011]. Altogether, these limita-
tions should be taken into account when consid-
ering the prognostic value of US-PD assessment 
of disease activity. A particular setting in which 
US-PD may provide valuable information for 
disease prognostication is the state of clinical 
remission or low disease activity. Here indeed 
inflammatory findings on US-PD are commonly 
seen [Brown et al. 2006, 2008; Scirè et al. 2009], 
and both grayscale synovial hypertrophy and PD 
synovitis have been demonstrated to be inde-
pendent predictors of structural progression on 
radiographs [Brown et al. 2008]. Owing to the 
lack of comparison between the predictive value of 
manual SJCs and US-PD scores in these patients, 
however, the superiority of imaging techniques 
compared with physical examination remains to 
be demonstrated.
Similarly to US-PD, synovitis detected through 
magnetic resonance imaging (MRI) does not 
appear predictive of radiographic erosions when 
assessed at baseline in active disease [McQueen 
et al. 2003; Bøyesen et al. 2011], again confirming 
the weak prognostic value of single time measures. 
Accordingly, a recent systematic review reported 
a variable ability of MRI findings to predict 
radiographic progression (range 18–100% for 
sensitivity and 5.9–97% for specificity), thus 
not recommending its routine clinical use [Suter 
et al. 2011]. MRI, however, can uniquely visualize 
another relevant inflammatory lesion in RA, the 
bone marrow edema (BME), which appears as an 
increased signal intensity on fat-suppressed 
T2-weighted, proton density or short tau inver-
sion recovery (STIR) pulse sequences, consistent 
with increased water content [Østergaard et al. 
2003]. Although BME is not specific for RA, 
its histopathological characterization in long-
standing disease has consistently shown that 
BME truly corresponds to intramarrow inflam-
mation [Jimenez-Boj et al. 2007; McQueen et al. 
2007]. Differently from synovitis, BME appears 
as a strong predictor of radiographic progression 
in both early and established disease even 
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when single baseline assessments are performed 
[McQueen et al. 1999; Hetland et al. 2009, 2010; 
Bøyesen et al. 2011]. In particular, in the study 
by Hetland and colleagues, the predictive value 
of MRI was investigated in a standardized treat-
ment setting against a number of other relevant 
prognostic factors, such as immunologic (ACPA, 
IgM RF, IgA RF), environmental (smoking, 
educational level), genetic (shared epitope) and 
disease activity markers [Hetland et al. 2009]. In 
this comprehensive model, MRI BME at presen-
tation was the strongest independent predictor 
of radiographic progression 2 years later in early 
RA patients as determined in both multivariable 
linear and logistic regression analyses. The 5-year 
extension study in the same cohort confirmed 
the predictive ability of BME in the long term 
[Hetland et al. 2010]. The different prognostic 
significance of the assessment of BME at base-
line compared with synovitis is currently unex-
plained. Whether BME represents a more sustained 
inflammatory process remains to be demonstrated, 
and different accessibility of the subchondral 
bone marrow compartment to treatment and/or 
different cellular composition of the inflamma-
tory infiltrates are only speculative possibilities.
Synovial tissue analysis
Histological and molecular analyses of the syno-
vial membrane ideally represent the gold stand-
ard for the assessment of joint inflammation in 
RA. The synovial tissue indeed undergoes early 
inflammatory changes, which include resident 
cell activation and infiltration by hematopoietic 
cells [Hitchon and El-Gabalawy, 2011], that can 
be clearly recognized even when clinical signs of 
arthritis are lacking [Kraan et al. 1998]. Compared 
with clinical and imaging assessments, examina-
tion of the synovial tissue offers the potential 
advantage of capturing both quantitative and 
qualitative features of the inflammatory process 
of RA. The rheumatoid lesion is indeed charac-
terized by a high degree of cellular and molecular 
heterogeneity across different disease phases and 
clinical subsets [Bugatti et al. 2011a]. The patho-
physiological background and the clinical corre-
lates of such heterogeneity have only in part 
started to be understood. Synovial tissue analysis 
is therefore at present mainly a research area, 
with limited clinical value in daily practice. 
However, as synovitis is the primary event under-
lying signs and symptoms of arthritis in RA, 
increasing efforts are being made in order to 
identify synovial prognostic biomarkers that 
could be used in individual patients [de Hair et al. 
2011]. The widespread diffusion of mini-invasive 
techniques for synovial sampling has recently 
made the clinical use of synovial tissue analysis a 
more realistic goal. Major drawbacks that need to 
be considered in light of the potential for clinical 
translation include the fact that synovial biopsy, 
although ‘mini’, remains an invasive procedure 
and requires some technical skills and facilities 
that might ultimately influence the outcome. In 
addition, the synovial tissue is more easily acces-
sible in larger joints such as the knee, which is 
generally affected in patients with a more aggres-
sive disease course. This could account for selec-
tion bias. Finally, although multiple sampling 
from different locations within the joint is cur-
rently recommended [van de Sande et al. 2011], 
overestimation or underestimation of inflamma-
tion due to the wide heterogeneity of the syn-
ovium cannot be excluded completely.
A number of independent studies have tried to 
identify the microscopic and molecular factors 
possibly associated with joint damage progression 
in RA. One of the cell populations which has his-
torically attracted great interest are synovial mar-
cophages. It is widely accepted that the number of 
CD68+ macrophages in the sublining strongly 
correlates with local disease activity [Tak et al. 
1997] and systemic inflammation [Baeten et al. 
2005], and is sensitive to change following active 
antirheumatic therapies [Haringman et al. 2005]. 
The dynamic correlation of tissue macrophages 
with the levels of ongoing inflammation, however, 
intrinsically limits their possible long-term prog-
nostic value as a single time measure. The asso-
ciation between the degree of synovial macrophage 
infiltration and the development of bone erosions 
at follow up appears indeed highly controversial 
[Mulherin et al. 1996; Kraan et al. 2004]. The 
same applies to macrophage-derived cytokines, 
none of which has been shown to accurately 
predict joint damage progression in RA [Rooney 
et al. 2010].
Another relevant aspect of synovial tissue hetero-
geneity with possible pathophysiologic and clini-
cal value is the degree and local organization of 
infiltrating T and B lymphocytes, which have 
been classically described as either randomly 
distributed within the sublining or spatially 
grouped into discrete lymphoid microenviron-
ments [Takemura et al. 2001]. The functional 
properties associated with the development of 
T–B cell niches in the context of the chronically 
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inflamed synovium are beyond the scope of this 
review and have been extensively summarized 
elsewhere [Manzo et al. 2010]. Different lymphoid 
patterns are also been intensively investigated for 
their possible translational value. Depending on 
the histological criteria adopted to identify lym-
phocytic aggregates as well as the cutoff values 
set for defining lymphoid aggregation, different 
clinical studies yielded partly conflicting conclu-
sions on whether these structures are associated 
with more severe RA subsets in terms of radio-
graphic damage [Klimiuk et al. 2003; Thurlings 
et al. 2008; Cañete et al. 2009]. However, it 
appears that the more selectively we look at 
specific B-cell-centered processes the more unfa-
vorable outcomes we capture. When B cells are 
analyzed as core elements of the process of 
lymphocytic aggregation, indeed, increasing 
degrees of B-cell infiltration appear to be asso-
ciated with a higher prevalence of erosive disease 
cross-sectionally, in parallel with an unbalanced 
molecular milieu favoring bone remodeling 
[Bugatti et al. 2011b]. These same findings are 
true when other cell populations of the B-cell 
lineage are analyzed, such as CD79a+ B cells 
[Mo et al. 2011]. Whether B-cell-rich synovitis 
and bone erosions are parallel manifestations of 
a more severe disease subset or are temporarily 
distinct phenomena remains to be demonstrated. 
Furthermore, as B cells are precursors of anti-
body-producing cells and autoantibodies are 
recognized as relevant prognostic factors in 
erosive RA, the clinical value of synovial B-cell 
infiltration theoretically may not be independent 
from the autoantibody status. The relationship 
between synovial lymphoid aggregates and 
RA-specific autoantibodies is however not une-
quivocal. Whilst previous studies have suggested 
that the process of lymphocytic aggregation is 
neither restricted nor preferentially associated 
with autoantibody positivity [Thurlings et al. 
2008; Cantaert et al. 2008], recent data obtained 
in murine chimeric systems demonstrated a 
significant relationship between synovial B-cell 
niches and ongoing production of ACPA [Humby 
et al. 2009]. Overall, the independent prognostic 
value of synovial B-cell infiltration is at present 
nondeterminable, and prospective studies in early 
RA are awaited.
Synovial tissue biomarkers in  
peripheral blood
Overall, the specificity of clinical and imaging 
assessments of inflammation at disease onset is 
too low to make such variables fully predictive of 
joint damage progression in RA. On the other 
hand, synovial tissue analysis is still in its infancy 
in terms of clinical translation. Great efforts are 
thus being made in order to identify novel varia-
bles which reliably reflect the pathophysiological 
cascade of RA and which can be used as prognos-
tic markers of disease severity. In this field, sero-
logical biomarkers reflecting bone and cartilage 
destruction are emerging as valid tools and have 
been the subject of a recent review [Karsdal et al. 
2011]. As bone and cartilage turnover represent 
the downstream effect of joint inflammation, 
equal attention is in parallel being paid to possible 
biomarkers of synovitis.
C-reactive protein (CRP) and ESR are only 
indirectly linked to synovitis. The acute phase 
proteins are indeed primarily produced by hepat-
ocytes in response to interleukins (IL) released 
during inflammation [Gabay and Kushner, 1999]. 
Although the predictive value of ESR and, to a 
lesser extent, of CRP for radiographic progression 
has been proposed in several independent studies 
[Combe et al. 2001; Lindqvist et al. 2003, 2005], 
their value compared with physical examination 
appears overall poor [Aletaha et al. 2011]. 
Disappointingly, however, none of the cytokines 
that drive the acute systemic response and that 
can be produced at least in part at the synovial 
tissue level, such as IL-1, IL-6 and TNF-α, has 
been convincingly shown to be associated with 
progression of joint damage [Roux-Lombard et al. 
2001; Rooney et al. 2010], thus making the crude 
assessment of classical inflammatory biomarkers 
hardly advisable.
Additional value could be provided by serologi-
cal markers which reflect more specific aspects 
of synovial pathology, differently regulated in 
different patients, such as angiogenesis (and vas-
cular biology in general) and mononuclear cell 
infiltration. The degree of activation of the vas-
cular endothelium, as assessed through E-selectin 
serum levels, has been shown to be associated 
with progression of joint destruction in early RA 
[Kuuliala et al. 2002], and similar data have been 
also provided for vascular endothelial growth 
factor (VEGF) [Ballara et al. 2001]. More 
recently, markers of different T-cell subsets, such 
as granzyme B and IL-22, have been shown to be 
elevated in the serum of RA patients in associa-
tion with radiographic progression [Goldbach-
Mansky et al. 2005; Leipe et al. 2011]. Overall, 
the specificity and predictive value of such 
Therapeutic Advances in Musculoskeletal Disease 4 (4)
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markers would however need confirmation in 
further studies.
An emerging peripheral biomarker of synovitis is 
the chemokine CXCL13. CXCL13 is involved in 
the positioning, cooperation and activation of B 
and T cells within lymphoid and extralymphoid 
sites, including RA synovium [Loetscher and 
Moser, 2002; Manzo et al. 2010]. Peripheral blood 
and serum expression of CXCL13 are increased 
in RA patients compared with healthy donors 
[Manzo et al. 2008; Rioja et al. 2008; Rosengren 
et al. 2011], and preliminary results indicate a sig-
nificant correlation between serum and synovial 
tissue levels of CXCL13 [Rosengren et al. 2011]. 
CXCL13 appears as a marker of severity in RA. A 
large prospective study has indeed shown that 
early RA patients with the highest levels of serum 
CXCL13 are those with the highest rate of pro-
gression of joint damage over long-term follow 
up [Meeuwisse et al. 2011]. In line with these 
data, we could demonstrate that serum levels of 
CXCL13 in untreated patients with disease dura-
tion <12 months are associated with clinical and 
US synovitis and predict US-PD signal persis-
tence [Bugatti et al. 2012]. Importantly, both in 
the study by Meeuwisse and colleagues and in our 
previous study, the predictive value of CXCL13 
was independent of the level of inflammation indi-
cated by the CRP level as well as the ACPA status 
[Meeuwisse et al. 2011; Bugatti et al. 2012]. Thus, 
although larger, prospective, confirmatory studies 
are needed, there may be opportunities to identify 
peripheral blood biomarkers capable of reflecting 
synovial pathology and predicting clinical out-
comes in RA.
Conclusions
Patients with different outcomes are still difficult 
to identify in the earliest stages of the disease, 
and RA phenotypic heterogeneity remains largely 
unpredictable. As joint damage progression is the 
result of the cumulative burden of inflammation 
over time, the identification of disease variables 
associated with persistent, refractory joint inflam-
mation could provide valuable tools to determine 
which patient is to run a more severe and rapid 
radiographic course. Joint inflammation can now 
be assessed through a variety of different tech-
niques able to provide increasing information on 
tissue pathobiology. Achievements in the field of 
synovial tissue analysis and biomarkers of synovitis 
in the peripheral blood represent only the first 
steps of the ongoing progress and cannot currently 
guide clinical decision making. Further research is 
needed to integrate clinical, imaging and biologic 
studies into comprehensive models able to accu-
rately predict disease severity and stratify patients 
into prognostic subgroups.
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